Loading...
33 exercise COVID-19 controlled studies
39% improvement, RR
0.61
[0.54-0.69]
https://c19early.com/exmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hamer
28%
0.72 [0.61-0.87]
hosp.
n/a
n/a
Improvement, RR [CI]
Treatment
Control
Hamer
34%
0.66 [0.55-0.79]
hosp.
n/a
n/a
Brawner
74%
0.26 [0.11-0.58]
hosp.
n/a
n/a
Zhang
26%
0.74 [0.48-1.14]
death
n/a
n/a
Zhang
18%
0.82 [0.69-0.96]
cases
n/a
n/a
Tavakol
69%
0.31 [0.10-1.02]
severe case
3/64
19/124
Yates
45%
0.55 [0.38-0.79]
death
72/163,912
62/30,119
Yates
47%
0.53 [0.43-0.66]
severe case
291/163,912
180/30,119
Holt
17%
0.83 [0.63-1.09]
cases
n/a
n/a
Cho
53%
0.47 [0.26-0.87]
death
case control
Cho
10%
0.90 [0.86-0.95]
cases
case control
Sallis
59%
0.41 [0.22-0.76]
death
11/3,118
170/6,984
Sallis
42%
0.58 [0.40-0.85]
ICU
32/3,118
195/6,984
Sallis
53%
0.47 [0.38-0.58]
hosp.
99/3,118
732/6,984
Christensen
63%
0.37 [0.16-0.85]
death
543 (n)
529 (n)
Christensen
23%
0.77 [0.52-1.15]
cases
55/543
77/529
Latorre-Román
76%
0.24 [0.05-1.04]
hosp.
n/a
n/a
Latorre-Román
87%
0.13 [0.01-1.17]
hosp.
n/a
n/a
Marcus
42%
0.58 [0.48-0.71]
symp. case
240/10,627
134/3,708
Yuan
91%
0.09 [0.01-1.65]
death
0/61
6/103
Yuan
70%
0.30 [0.09-0.92]
severe case
3/61
26/103
Brandenburg
-6%
1.06 [0.23-4.79]
hosp.
102 (n)
39 (n)
Brandenburg
78%
0.22 [0.05-1.02]
hosp.
177 (n)
34 (n)
Brandenburg
64%
0.36 [0.13-0.98]
hosp.
97 (n)
34 (n)
Brandenburg
35%
0.65 [0.28-1.48]
severe case
102 (n)
39 (n)
Brandenburg
24%
0.76 [0.28-2.04]
severe case
52 (n)
34 (n)
Bielik
30%
0.70 [0.40-1.21]
mod. case
775 (n)
365 (n)
Bielik
-9%
1.09 [0.69-1.73]
cases
775 (n)
365 (n)
Lee
74%
0.26 [0.07-0.99]
death
2/11,072
32/41,293
Lee
58%
0.42 [0.19-0.91]
severe case
39/11,072
273/41,293
Lee
16%
0.84 [0.73-0.98]
cases
291/11,072
1,293/41,293
Maltagliati
52%
0.48 [0.25-0.87]
hosp.
n/a
n/a
Baynouna AlKetbi
98%
0.01 [0.00-0.44]
death
n/a
n/a
Ahmadi
30%
0.70 [0.54-0.89]
death
160/232,613
112/95,221
Nguyen
20%
0.80 [0.72-0.88]
symp. case
904/2,836
483/1,111
Lin
47%
0.53 [0.12-2.33]
cases
n/a
n/a
de Souza
73%
0.27 [0.07-1.06]
ventilation
3/611
6/327
de Souza
34%
0.66 [0.43-0.99]
hosp.
49/611
42/327
Mohsin
19%
0.81 [0.66-0.99]
severe case
86/258
224/544
Mohsin
-1%
1.01 [0.88-1.15]
severe case
290/698
224/544
Ekblom-Bak
48%
0.52 [0.30-0.92]
severe case
n/a
n/a
Lengelé
74%
0.26 [0.07-0.80]
cases
23/229
4/12
Saadeh
9%
0.91 [0.56-1.43]
symp. case
362 (n)
225 (n)
Saadeh
4%
0.96 [0.62-1.43]
symp. case
362 (n)
225 (n)
Hamrouni
29%
0.71 [0.55-0.92]
death
138/106,006
109/47,827
Huang
47%
0.53 [0.23-1.22]
severe case
7/74
16/90
Huang
8%
0.92 [0.30-2.85]
severe case
3/23
20/141
Huang
66%
0.34 [0.17-0.70]
cases
n/a
n/a
Steenkamp
42%
0.58 [0.50-0.68]
death
29,469 (n)
13,366 (n)
Steenkamp
45%
0.55 [0.47-0.64]
ventilation
29,469 (n)
13,366 (n)
Steenkamp
41%
0.59 [0.52-0.66]
ICU
29,469 (n)
13,366 (n)
Gilley
-42%
1.42 [0.60-3.35]
cases
172/1,917
5/79
Beydoun
43%
0.57 [0.32-1.01]
cases
1,710 (n)
448 (n)
Beydoun
62%
0.38 [0.18-0.78]
cases
672 (n)
448 (n)
Salgado-Aranda
83%
0.17 [0.05-0.56]
death
4/223
41/297
Paul
38%
0.62 [0.30-1.20]
no recov.
n/a
n/a
Paul
4%
0.96 [0.53-1.63]
no recov.
n/a
n/a
Kontopoulou
66%
0.34 [0.24-0.47]
recov. time
42 (n)
24 (n)
Kontopoulou
67%
0.33 [0.24-0.46]
no recov.
42 (n)
24 (n)
exercise COVID-19 outcomes
c19early.com/ex May 2022
Favors exercise
Favors inactivity
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit